secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0000917520-24-000092
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds
--------------------------------------------------------------------------------

- GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
- Revenue $418.2M, up 9.7% reported, 2.3% organic; organic ex-Boston +0.3%. Adjusted gross margin 65.2% (down from 67.6%).
- Codman Specialty Surgical rev $301.8M (+11.3% reported, +0.9% organic). Tissue Technologies $116.4M (+5.6% reported, +5.7% organic; -1% ex-Boston).
- FY2024 guidance cut: revenue $1.609-1.629B, adjusted EPS $2.41-2.57. Cites temporary shipping holds and investments in quality/GMP compliance.
- Received PMA approvable for SurgiMend pending GMP certification; Braintree facility operational readiness expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/0000917520-24-000092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752024000092/iart-20240729.htm
  HTML page:      https://secwatch.observer/filing/0000917520-24-000092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer